MacroGenics announces closing of collaboration and license agreement with Janssen
MacroGenics announced the closing of the global collaboration and license agreement for MGD011 with Janssen Biotech announced Dec. 22, 2014. MacroGenics will receive a $50 million upfront license fee and Johnson & Johnson Innovation has invested $75 million. January 27, 2015